- Home
- JJSF vs ACAD Comparison
JJSF vs ACAD Comparison
Compare JJSF & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JJSF
- ACAD
- Stock Information
- Founded
- JJSF 1971
- ACAD 1993
- Country
- JJSF United States
- ACAD United States
- Employees
- JJSF N/A
- ACAD N/A
- Industry
- JJSF Specialty Foods
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- JJSF Consumer Staples
- ACAD Health Care
- Exchange
- JJSF Nasdaq
- ACAD Nasdaq
- Market Cap
- JJSF N/A
- ACAD 2.5B
- IPO Year
- JJSF N/A
- ACAD 2004
- Fundamental
- Price
- JJSF $115.74
- ACAD $16.93
- Analyst Decision
- JJSF Buy
- ACAD Buy
- Analyst Count
- JJSF 2
- ACAD 15
- Target Price
- JJSF $142.50
- ACAD $24.21
- AVG Volume (30 Days)
- JJSF 144.2K
- ACAD 1.7M
- Earning Date
- JJSF 05-06-2025
- ACAD 05-07-2025
- Dividend Yield
- JJSF 2.69%
- ACAD N/A
- EPS Growth
- JJSF N/A
- ACAD N/A
- EPS
- JJSF 3.89
- ACAD 1.37
- Revenue
- JJSF $1,585,410,000.00
- ACAD $996,283,000.00
- Revenue This Year
- JJSF $5.67
- ACAD $13.07
- Revenue Next Year
- JJSF $3.43
- ACAD $10.06
- P/E Ratio
- JJSF $29.85
- ACAD $12.55
- Revenue Growth
- JJSF 0.49
- ACAD 22.42
- 52 Week Low
- JJSF $112.27
- ACAD $13.40
- 52 Week High
- JJSF $180.80
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- JJSF 33.60
- ACAD 64.73
- Support Level
- JJSF $112.40
- ACAD $14.45
- Resistance Level
- JJSF $132.14
- ACAD $15.31
- Average True Range (ATR)
- JJSF 4.94
- ACAD 0.66
- MACD
- JJSF -1.92
- ACAD 0.27
- Stochastic Oscillator
- JJSF 11.03
- ACAD 90.91
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.